ArticleNeuro-oncology practice2024
Antidepressants and survival in glioma-A registry-based retrospective cohort study.
Article in Neuro-oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Antidepressant drugs and risk of developing glioma: a national registry-based case-control study and a meta-analysis.American journal of epidemiology · 2024Pooled it
- Intratumoral serotonin and antidepressants in glioblastoma patients: narrowing the uncertainties.Journal of neuro-oncology · 2026Article
- Addressing the serotonin hypothesis of depression through analyses of genetics, methylation and metabolite variations in glioma patients.Scientific reports · 2025Article
- Survival outcomes associated with antidepressant use in glioblastoma: a cohort study.Journal of neuro-oncology · 2025Article
- Antidepressants and survival in glioma: Unraveling a complex puzzle.Neuro-oncology practice · 2024Article
- The effect of antidepressants on glioblastoma survival: A systematic review and meta-analysis.Neuro-oncology advancesReview
- Impact of antidepressant use on survival outcomes in glioma patients: A systematic review and meta-analysis.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depression and treatment with antidepressant medication is common in patients with malignant glioma. However, the extent to which antidepressants may affect the disease is not fully understood. Therefore, the purpose of the present study was to investigate possible associations between treatment with antidepressant medication and survival in glioma patients. Methods: We performed a registry-based cohort study including 1231 patients with malignant glioma (WHO grades 2, 3, and 4) having undergone surgery, and 6400 matched controls without glioma. All data were extracted from the RISK North database, which contains information from multiple national population-based registries in Sweden. Results: Treatment with antidepressants is more common in patients with malignant glioma (27%), compared to controls (16%), Conclusions: Our results demonstrate a negative association between antidepressant medication and survival in glioma. Further research will be needed to clarify causation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.